Endocare
This article was originally published in The Gray Sheet
Executive Summary
Firm signs OEM agreement with Qualigen Inc. that will allow Endocare to include Qualigen's 15-minute total prostate specific antigen test into Endocare's diagnostic station for urology, firm announces June 4. The five-year agreement specifies one year of exclusivity with the option to extend exclusivity. Integrating Qualigen's PSA test into the workstation will allow patients quicker access to their total PSA scores, which are used in the diagnosis and management of prostate cancer, Endocare says. The new workstation and its associated diagnostic technology were exhibited at the AUA meeting